Background: The purpose of this study was to assess the prevalence of vancomycin-resistant enterococci (VRE) in urinary isolates in North America, and the activity of various antibiotics against VRE. 
Introduction
Enterococci are constitutive members of the intestinal flora of humans and animals and may also colonize the upper respiratory tract, biliary tracts and vaginas of otherwise healthy persons. [1] [2] [3] [4] Enterococci have been documented to cause infection of the urinary tract and other sites. [4] [5] [6] [7] Although more than one dozen species of Enterococcus have been identified, Enterococcus faecalis and Enterococcus faecium account for approximately 85-90% and 5-10% of human enterococcal infections, respectively. [1] [2] [3] [4] Vancomycin-resistant enterococci (VRE), especially E. faecium are prevalent in hospitalized patient populations across the United States and are endemic in a number of healthcare institutions. [2] [3] [4] 8 In Canada, the prevalence of VRE infection and colonization is presently low (<1%). 9 Urinary tract infections (UTI) are the most common nosocomial infections caused by enterococci, including vancomycin-resistant strains. 1, 4 Urinary tract infections have been reported to account for 34-46% of all infections in the hospital and occur at a rate of 12.9 cases/1000 discharges. 6 In addition to UTI, vancomycin-resistant enterococci have also been associated with asymptomatic bacteriuria, colonization of the urinary tract and symptomatic disease such as cholecystitis, cholangitis, peritonitis, septicaemia, endocarditis, meningitis and simple wound infections. [1] [2] [3] [4] [5] [6] [7] Management of VRE infections poses a clinical challenge as these organisms may be resistant to several antimicrobials with unique mechanisms of action. 2, 4, 11 The purpose of this study was three-fold: 1) to assess the prevalence of urinary tract infections caused by VRE in major centres across North America; 2) to assess the activity of various antibiotics against urinary isolates of VRE and 3) to identify the genetic determinants of glycopeptide resistance.
Materials and methods

Study centres
Twenty-eight medical centres representing seven of nine regions of the United States Bureau of the Census and 10 Canadian centres representing all geographic regions were involved in this study (Table 1) .To assess the prevalence of VRE in urinary isolates in US institutions, the chief clinical microbiologist was asked to provide information regarding the number of urine cultures processed per year in their institution, as well as the number of enterococcal species identified per year and the number of VRE (E. faecalis, E. faecium) obtained per year from urine cultures.
Collection of isolates
Each study site was asked to collect up to a maximum of 50 consecutive urinary isolates of VRE (E. faecium, E. faecalis only), one isolate per Centre/city patient. Study centres were asked to culture and identify significant VRE urinary isolates as per their standard laboratory practice. Isolates were transported to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada) on Amies charcoal swabs as previously described. 12 Upon receipt, isolates were cultured by the coordinating laboratory and isolate identities were confirmed. 13, 14 All isolates were stocked in skimmed milk and stored at -70°C awaiting reference antibiotic susceptibility testing.
Antibiotic susceptibility testing
Before antibiotic susceptibility testing, isolates were cultured twice onto blood agar. All antibiotics for susceptibility testing were obtained as laboratory-grade powders from their respective manufacturers. MICs were determined by standard NCCLS broth microdilution methods with Mueller-Hinton broth and were interpreted using NCCLS breakpoints. 15 ≤1, 2 and ≥4; linezolid, ≤2, 4 and ≥8; gentamicin, <500 and ≥500; streptomycin, <1000 and ≥1000.
PCR for vanA and vanB
To determine the prevalence of vanA and vanB glycopeptide resistance genotypes among VRE, a multiplex PCR assay was carried out as described by Dutka-Malen et al., 17 with some modifications. PCR was carried out using a Perkin-Elmer GeneAmp PCR System 9700 with the following parameters: 94°C for 4 min, 30 cycles at 94°C for 1 min, 58°C for 45 s and 72°C for 1 min, and a final cycle at 72°C for 10 min.
Results
Prevalence of VRE survey
Responses regarding the prevalence of VRE urinary isolates were received from all 28 (100%) US medical centres studied and represented seven of nine geographic regions of the United States Bureau of the Census (Table 1) . The mean ± S.D. number of urine cultures processed per year was 24 150 ± 15 953, from which 1044 ± 936 (5.0 ± 4.1%) enterococcal isolates were recovered ( Table 2 ). The Table 3) . Of the 697 VRE, 74.2% were inpatient urinary isolates, 24.8% were outpatient isolates and 1% were unknown. In total, 69.9% of all urinary isolates were obtained from female patients, whereas 30.1% were obtained from male subjects. Breakdown of isolates by age was as follows: ≤16 years, 1.0%; 17-64 years, 42.8%; ≥65 years, 53.8%; unknown, 2.4%. The 10 Canadian medical centres isolated and submitted a total of three VRE. All three organisms were obtained from the same centre, were identified as vanA-positive E. faecium and were genetically indistinguishable by pulsed-field gel electrophoresis (data not shown).
Antibiotic susceptibility and PCR determination of VRE
The activity of various antibiotics against VRE is displayed in 
Discussion
Several US studies have reported dramatic increases in the colonization and prevalence of infections caused by VRE. 4, 8, 18 Very few studies, however, have described the epidemiology and clinical importance of VRE in urinary isolates. In one 18 month evaluation of patients with positive urine cultures at a tertiary care hospital, 13 of 98 (13.3%) patients with positive cultures had symptomatic UTIs, giving an overall rate of 2.8 VRE UTI per 10 000 patient admissions. 19 Another study of 28 VRE-infected patients found that only seven (28%) had UTI, 20 whereas a recent prospective culture prevalence survey of residents in 25 long-term care facilities found that 124 of 373 (33.2%) urine cultures were positive for enterococci and that 32 (25.8%) of those 124 enterococcal isolates were vancomycinresistant. 21 Our study demonstrated that vancomycin-resistant enterococci urinary isolates are present throughout most regions of the United States and represent approximately 9.2% of all enterococci isolated as well as 0.37% of all urine cultures processed. Actual VRE prevalence rates, however, were highly variable from centre to centre, ranging from 1.0% to as high as 26.1% in some centres. In Canada, the prevalence of VRE infection and colonization is still very low (<1%). For this reason, published studies frequently study colonization rather than infection. 9, 10 In this study, 10 Canadian geographically dispersed centres isolated and submitted only three VRE isolates, suggesting that VRE continues to be isolated infrequently in Canada. These data are consistent with previous studies, which have consistently reported a low prevalence of VRE colonization and infection throughout Canada. 9, 10 Vancomycin-resistant enterococci obtained from urinary isolates were primarily vancomycin-resistant E. faecium (88.4%) and approximately 75% of these strains displayed a VanA phenotype; 22 83.8% of all VRE and 87.3% of vancomycin-resistant E. faecium were shown by PCR to carry the vanA gene. Although the majority of VRE isolates were vanA-positive, vanB was the predominant genotype in two of 28 (7.1%) centres. These data indicate that despite the predominance and widespread distribution of the vanA resistance determinant, the vanB genotype has become well established and shows remarkable stability in some US institutions. The most active agents against all VRE isolates (E. faecium and E. faecalis) were linezolid, nitrofurantoin and chloramphenicol, with 0.3%, 0.6% and 2.4% resistance, respectively. Specifically against urinary isolates of vancomycin-resistant E. faecium, the most active agents were linezolid, chloramphenicol and nitrofurantoin, with 0.3%, 0.3% and 0.5% resistance, respectively. The excellent activity of linezolid and nitrofurantoin against VRE has been previously reported. 5, 10, 23 Against vancomycin-resistant E. faecium, quinupristin/dalfopristin maintained activity in the majority of patients, with only 3.5% resistance. Ampicillin and ciprofloxacin, however, displayed almost universal resistance. The poor activity of fluoroquinolones and ampicillin against vancomycin-resistant E. faecium has been reported previously. 11 Two isolates of vancomycin-resistant E. faecium demonstrated high level resistance to linezolid (MIC, 16 mg/L) which, although rare, has been previously reported. 24 In conclusion, VRE urinary isolates are present throughout the United States, as reported by every medical centre in this study, and are very susceptible to linezolid, nitrofurantoin and chloramphenicol. In Canada, VRE urinary isolates are rare. Glycopeptide susceptibilities and PCR show that the vanA genotype is widely disseminated amongst VRE isolated in North America.
